page_title: Pantoprazole
section_title: Pharmacology
hierarchical_section_title: Pantoprazole / Pharmacology
caption_attribution_description: English: Drug Name: Pantoprazole 20 MG (pantoprazole sodium sesquihydrate 22.6 MG) Delayed ReleaseTablet Ingredient(s): Pantoprazole Drug Label Imprint: P;20 Color(s): Yellow Shape: Oval Size (mm): 9.00 Score: 1 Inactive Ingredient(s): ShowHide calcium stearate / crospovidone / ferric oxide yel... calcium stearate / crospovidone / ferric oxide yellow / mannitol / methacrylic acid - ethyl acrylate copolymer (1:1) type a / polysorbate 80 / povidone k25 / povidone k90 / propylene glycol / sodium carbonate / sodium lauryl sulfate / titanium dioxide / triethyl citrate / hypromellose 2208 (100 mpa.s) Drug Label Author: Wyeth Pharmaceuticals Company, a subsidiary of Pfizer Inc. DEA Schedule: Non-scheduled
context_page_description: Pantoprazole, sold under the brand name Protonix among others, is a medication used for the treatment of stomach ulcers, short-term treatment of erosive esophagitis due to gastroesophageal reflux disease, maintenance of healing of erosive esophagitis, and pathological hypersecretory conditions including Zollinger–Ellison syndrome. It may also be used along with other medications to eliminate Helicobacter pylori. Effectiveness is similar to other proton pump inhibitors. It is available by mouth and by injection into a vein.
  Common side effects include headaches, diarrhea, vomiting, abdominal pain, and joint pain. More serious side effects may include severe allergic reactions, a type of chronic inflammation known as atrophic gastritis, Clostridium difficile colitis, low magnesium, and vitamin B12 deficiency. Use in pregnancy appears to be safe. Pantoprazole is a proton pump inhibitor that decreases gastric acid secretion. It works by inactivating-ATPase function in the stomach.
  Study of pantoprazole began in 1985, and it came into medical use in Germany in 1994. It is available as a generic medication.
context_section_description: The mechanism of action of pantoprazole is to inhibit the final step in gastric acid production. In the gastric parietal cell of the stomach, pantoprazole covalently binds to the H+/K+ ATP pump to inhibit gastric acid and basal acid secretion. The covalent binding prevents acid secretion for up to 24 hours and longer.
  Pantoprazole is metabolized in the liver by the cytochrome P450 system. Metabolism mainly consists of demethylation by CYP2C19 followed by sulfation. Another metabolic pathway is oxidation by CYP3A4. Pantoprazole metabolites are not thought to have any pharmacological significance. It is usually given with a prokinetic drug because of inactivity in the acidic environment of the stomach. Pantoprazole binds irreversibly to H+K+ATPase (proton pumps) to suppress the secretion of acid. Due to irreversible binding of the pumps, new pumps have to be made before acid production can be resumed. The drug's plasma half-life is about two hours.
caption: Wyeth pantoprazole 20-mg
exif: {"Image ImageDescription": "0008-0606-01", "Image XResolution": "72", "Image YResolution": "72", "Image ResolutionUnit": "Pixels/Inch", "Image Software": "www.medicosconsultants.com - Medicos Consultants Imaging CMS v2.17", "Image YCbCrPositioning": "Centered", "Image XPComment": "[77, 0, 101, 0, 100, 0, 105, 0, 99, 0, 111, 0, 115, 0, 32, 0, 67, 0, 111, 0, ... ]", "Image XPAuthor": "NLM - Medicos Consultants", "Image XPSubject": "[48, 0, 48, 0, 48, 0, 56, 0, 45, 0, 48, 0, 54, 0, 48, 0, 54, 0, 45, 0, 48, 0, 49, 0, 0, 0]"}